| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 68 | 2022 | 402 | 7.670 |
Why?
|
| Receptor, ErbB-2 | 19 | 2022 | 52 | 3.460 |
Why?
|
| Antineoplastic Agents | 20 | 2019 | 198 | 2.110 |
Why?
|
| Trastuzumab | 17 | 2021 | 26 | 2.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2022 | 242 | 1.460 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 68 | 1.230 |
Why?
|
| Antibodies, Monoclonal | 14 | 2011 | 174 | 1.140 |
Why?
|
| Biomarkers, Tumor | 9 | 2019 | 203 | 1.110 |
Why?
|
| Neoplasm Metastasis | 19 | 2019 | 102 | 0.940 |
Why?
|
| Female | 72 | 2022 | 14735 | 0.880 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 15 | 0.820 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2021 | 12 | 0.810 |
Why?
|
| Mastectomy, Segmental | 3 | 2021 | 29 | 0.750 |
Why?
|
| STAT6 Transcription Factor | 1 | 2020 | 11 | 0.670 |
Why?
|
| Humans | 77 | 2022 | 25972 | 0.670 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 11 | 0.640 |
Why?
|
| Middle Aged | 44 | 2021 | 8775 | 0.630 |
Why?
|
| Antibodies, Monoclonal, Humanized | 17 | 2014 | 86 | 0.630 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2019 | 4 | 0.630 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 55 | 0.630 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 37 | 0.620 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 11 | 0.600 |
Why?
|
| Tamoxifen | 7 | 2012 | 30 | 0.550 |
Why?
|
| Aromatase Inhibitors | 4 | 2012 | 9 | 0.540 |
Why?
|
| ErbB Receptors | 3 | 2008 | 54 | 0.520 |
Why?
|
| Adult | 37 | 2020 | 7665 | 0.470 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2012 | 19 | 0.460 |
Why?
|
| Aged | 34 | 2020 | 8732 | 0.440 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 31 | 0.430 |
Why?
|
| Receptors, Progesterone | 7 | 2019 | 26 | 0.420 |
Why?
|
| Aged, 80 and over | 18 | 2020 | 4642 | 0.410 |
Why?
|
| Carcinoma | 2 | 2011 | 68 | 0.410 |
Why?
|
| Estrogen Replacement Therapy | 3 | 1999 | 20 | 0.410 |
Why?
|
| Enzyme Inhibitors | 4 | 2006 | 116 | 0.390 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2016 | 82 | 0.370 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2014 | 16 | 0.340 |
Why?
|
| Cell Proliferation | 3 | 2020 | 173 | 0.340 |
Why?
|
| Hypertension | 3 | 2014 | 181 | 0.310 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 253 | 0.310 |
Why?
|
| Receptors, Estrogen | 8 | 2013 | 64 | 0.300 |
Why?
|
| Treatment Outcome | 14 | 2021 | 3400 | 0.300 |
Why?
|
| Prospective Studies | 5 | 2021 | 1702 | 0.290 |
Why?
|
| Neoplasm Staging | 11 | 2019 | 360 | 0.290 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2019 | 31 | 0.290 |
Why?
|
| Menopause | 2 | 2000 | 101 | 0.290 |
Why?
|
| Prognosis | 7 | 2018 | 784 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2019 | 206 | 0.250 |
Why?
|
| Genes, BRCA2 | 3 | 2020 | 10 | 0.240 |
Why?
|
| Genes, BRCA1 | 3 | 2020 | 12 | 0.240 |
Why?
|
| Disease-Free Survival | 6 | 2017 | 174 | 0.240 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 78 | 0.230 |
Why?
|
| Registries | 3 | 2021 | 192 | 0.220 |
Why?
|
| Survival Analysis | 7 | 2018 | 258 | 0.220 |
Why?
|
| Survival Rate | 5 | 2019 | 333 | 0.220 |
Why?
|
| Angina Pectoris | 1 | 2004 | 16 | 0.210 |
Why?
|
| Postmenopause | 5 | 2010 | 57 | 0.210 |
Why?
|
| Young Adult | 2 | 2019 | 1942 | 0.200 |
Why?
|
| Quinazolines | 2 | 2016 | 17 | 0.200 |
Why?
|
| Cancer Survivors | 1 | 2022 | 13 | 0.200 |
Why?
|
| Quality of Life | 9 | 2007 | 605 | 0.190 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 1758 | 0.190 |
Why?
|
| Quinolines | 2 | 2022 | 8 | 0.190 |
Why?
|
| Combined Modality Therapy | 5 | 2018 | 297 | 0.180 |
Why?
|
| Bevacizumab | 7 | 2014 | 22 | 0.180 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 368 | 0.170 |
Why?
|
| Disease Progression | 7 | 2011 | 655 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2013 | 76 | 0.170 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 14 | 0.170 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2020 | 6 | 0.170 |
Why?
|
| Menopause, Premature | 2 | 2000 | 7 | 0.170 |
Why?
|
| Stroke Volume | 2 | 2019 | 43 | 0.170 |
Why?
|
| Cell Survival | 1 | 2020 | 116 | 0.160 |
Why?
|
| Isoflavones | 1 | 2000 | 2 | 0.160 |
Why?
|
| Cohort Studies | 4 | 2019 | 1806 | 0.160 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 16 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 117 | 0.160 |
Why?
|
| Gene Targeting | 1 | 2019 | 10 | 0.160 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 6 | 0.160 |
Why?
|
| Phthalazines | 1 | 2019 | 6 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 13 | 0.160 |
Why?
|
| S Phase | 1 | 1999 | 11 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 43 | 0.160 |
Why?
|
| Fenretinide | 3 | 2010 | 5 | 0.160 |
Why?
|
| Odds Ratio | 2 | 2018 | 268 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 60 | 0.150 |
Why?
|
| Piperazines | 1 | 2019 | 84 | 0.150 |
Why?
|
| Chimerism | 1 | 2018 | 5 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 5 | 0.150 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 5 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 101 | 0.140 |
Why?
|
| Mammography | 3 | 2022 | 43 | 0.140 |
Why?
|
| Circulating Tumor DNA | 1 | 2017 | 5 | 0.140 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2017 | 13 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 40 | 0.130 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 32 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2019 | 437 | 0.130 |
Why?
|
| Paclitaxel | 4 | 2013 | 50 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 252 | 0.130 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 577 | 0.130 |
Why?
|
| Menstruation Disturbances | 1 | 1996 | 1 | 0.130 |
Why?
|
| Survivors | 4 | 2004 | 68 | 0.130 |
Why?
|
| Cytostatic Agents | 1 | 2016 | 2 | 0.130 |
Why?
|
| Ovary | 1 | 1996 | 22 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2016 | 273 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 46 | 0.120 |
Why?
|
| Aspirin | 1 | 2016 | 57 | 0.120 |
Why?
|
| Male | 7 | 2021 | 14280 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 2 | 1987 | 139 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1987 | 165 | 0.110 |
Why?
|
| Gene Amplification | 2 | 2013 | 21 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 488 | 0.110 |
Why?
|
| Maytansine | 1 | 2014 | 2 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 65 | 0.110 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1994 | 2 | 0.110 |
Why?
|
| Animals | 2 | 2019 | 3503 | 0.110 |
Why?
|
| Genes, erbB-2 | 2 | 2005 | 7 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2005 | 72 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 153 | 0.100 |
Why?
|
| Estrogens | 3 | 2000 | 26 | 0.100 |
Why?
|
| Mutation | 4 | 2018 | 341 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 3 | 2000 | 36 | 0.100 |
Why?
|
| Deoxycytidine | 3 | 2011 | 20 | 0.100 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2012 | 10 | 0.100 |
Why?
|
| Clinical Trials as Topic | 4 | 2005 | 210 | 0.100 |
Why?
|
| Ovariectomy | 1 | 2012 | 26 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 263 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 1993 | 135 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2012 | 49 | 0.090 |
Why?
|
| Drugs, Investigational | 1 | 2011 | 5 | 0.090 |
Why?
|
| Retrospective Studies | 7 | 2022 | 3358 | 0.090 |
Why?
|
| Safety | 5 | 2004 | 37 | 0.090 |
Why?
|
| Drug Administration Schedule | 4 | 2008 | 160 | 0.090 |
Why?
|
| Diet | 2 | 2002 | 197 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2000 | 2 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 2 | 2000 | 6 | 0.080 |
Why?
|
| Mastectomy | 1 | 2009 | 36 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 9 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2005 | 869 | 0.070 |
Why?
|
| Ki-67 Antigen | 2 | 2005 | 18 | 0.070 |
Why?
|
| Doxorubicin | 2 | 2004 | 57 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 17 | 0.070 |
Why?
|
| Lymphatic Metastasis | 2 | 2005 | 88 | 0.070 |
Why?
|
| Indoles | 1 | 2008 | 33 | 0.070 |
Why?
|
| Pyrroles | 1 | 2008 | 23 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 9 | 0.070 |
Why?
|
| Contraindications | 3 | 1998 | 29 | 0.070 |
Why?
|
| Longevity | 2 | 2000 | 29 | 0.070 |
Why?
|
| Etoposide | 1 | 1987 | 27 | 0.070 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2004 | 6 | 0.070 |
Why?
|
| Breast Self-Examination | 1 | 2007 | 3 | 0.070 |
Why?
|
| Keratin-6 | 1 | 2006 | 2 | 0.070 |
Why?
|
| Keratin-5 | 1 | 2006 | 2 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2003 | 20 | 0.060 |
Why?
|
| Drug Interactions | 2 | 1998 | 35 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 332 | 0.060 |
Why?
|
| Family | 1 | 2007 | 93 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2004 | 326 | 0.060 |
Why?
|
| Logistic Models | 3 | 2005 | 391 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 128 | 0.060 |
Why?
|
| Drug Evaluation | 7 | 1989 | 19 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 142 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2005 | 55 | 0.060 |
Why?
|
| Cardiovascular Diseases | 2 | 2000 | 307 | 0.060 |
Why?
|
| Mass Screening | 2 | 2022 | 170 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 133 | 0.060 |
Why?
|
| Gene Expression | 1 | 2005 | 200 | 0.060 |
Why?
|
| Recurrence | 1 | 2005 | 300 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2010 | 393 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2005 | 306 | 0.060 |
Why?
|
| Capecitabine | 3 | 2011 | 3 | 0.050 |
Why?
|
| Organic Chemicals | 1 | 2004 | 4 | 0.050 |
Why?
|
| Fluorouracil | 3 | 2011 | 46 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 1995 | 106 | 0.050 |
Why?
|
| Breast Density | 1 | 2022 | 4 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2020 | 390 | 0.050 |
Why?
|
| Hydroxamic Acids | 1 | 2002 | 4 | 0.050 |
Why?
|
| Nitriles | 1 | 2002 | 13 | 0.050 |
Why?
|
| Biomarkers | 2 | 2016 | 544 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2003 | 123 | 0.050 |
Why?
|
| Triazoles | 1 | 2002 | 29 | 0.050 |
Why?
|
| Heart Diseases | 2 | 2001 | 61 | 0.050 |
Why?
|
| Hospitalization | 1 | 2004 | 301 | 0.050 |
Why?
|
| Risk Factors | 4 | 2005 | 2237 | 0.050 |
Why?
|
| Vinblastine | 1 | 1981 | 7 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 102 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2002 | 82 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 367 | 0.040 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 8 | 0.040 |
Why?
|
| Genotype | 2 | 2014 | 339 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2020 | 19 | 0.040 |
Why?
|
| Health Behavior | 1 | 2002 | 157 | 0.040 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2000 | 1 | 0.040 |
Why?
|
| Embryonal Carcinoma Stem Cells | 1 | 2000 | 1 | 0.040 |
Why?
|
| Phytoestrogens | 1 | 2000 | 4 | 0.040 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2000 | 3 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2000 | 10 | 0.040 |
Why?
|
| Hot Flashes | 1 | 2000 | 11 | 0.040 |
Why?
|
| Plant Preparations | 1 | 2000 | 7 | 0.040 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2000 | 5 | 0.040 |
Why?
|
| Antigens, CD | 2 | 2017 | 50 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2013 | 36 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2000 | 35 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 34 | 0.040 |
Why?
|
| Weight Gain | 1 | 2000 | 59 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 1999 | 92 | 0.040 |
Why?
|
| Folic Acid | 1 | 2019 | 21 | 0.040 |
Why?
|
| Time Factors | 2 | 2002 | 1391 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 1999 | 25 | 0.040 |
Why?
|
| Taxoids | 2 | 2008 | 11 | 0.040 |
Why?
|
| Anthracyclines | 2 | 2008 | 17 | 0.040 |
Why?
|
| Flushing | 1 | 1998 | 3 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 1998 | 3 | 0.040 |
Why?
|
| Dyspareunia | 1 | 1998 | 6 | 0.040 |
Why?
|
| Vaginitis | 1 | 1998 | 3 | 0.040 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 1998 | 8 | 0.040 |
Why?
|
| Mood Disorders | 1 | 1998 | 25 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 1059 | 0.040 |
Why?
|
| Endometrial Neoplasms | 1 | 1998 | 26 | 0.040 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2017 | 6 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 55 | 0.030 |
Why?
|
| Cadherins | 1 | 2017 | 30 | 0.030 |
Why?
|
| Lung Neoplasms | 3 | 1989 | 543 | 0.030 |
Why?
|
| Obesity | 1 | 2000 | 297 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2011 | 13 | 0.030 |
Why?
|
| Osteoporosis | 1 | 1998 | 73 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 196 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2016 | 10 | 0.030 |
Why?
|
| Cardiotoxicity | 1 | 2016 | 8 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 1998 | 118 | 0.030 |
Why?
|
| Echocardiography | 1 | 2016 | 70 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 10 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2016 | 12 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 15 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 21 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 143 | 0.030 |
Why?
|
| Adolescent | 2 | 2019 | 2100 | 0.030 |
Why?
|
| United States | 2 | 2014 | 1990 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 16 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 33 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 90 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1994 | 10 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 1994 | 22 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 129 | 0.030 |
Why?
|
| Incidence | 1 | 1996 | 729 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 240 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 268 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2014 | 184 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 8 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2011 | 1 | 0.020 |
Why?
|
| Neuropilin-1 | 1 | 2011 | 4 | 0.020 |
Why?
|
| Neoplasms | 1 | 1994 | 230 | 0.020 |
Why?
|
| Night Blindness | 1 | 2010 | 2 | 0.020 |
Why?
|
| Cyclophosphamide | 2 | 2004 | 46 | 0.020 |
Why?
|
| Vidarabine Phosphate | 1 | 1989 | 1 | 0.020 |
Why?
|
| Arabinonucleotides | 1 | 1989 | 1 | 0.020 |
Why?
|
| Spiro Compounds | 1 | 1989 | 1 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 1989 | 17 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1989 | 18 | 0.020 |
Why?
|
| Premenopause | 1 | 2009 | 11 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2009 | 11 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1989 | 44 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 97 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 1989 | 75 | 0.020 |
Why?
|
| Haplotypes | 1 | 2008 | 55 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 117 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 68 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 11 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2008 | 1 | 0.020 |
Why?
|
| Alzheimer Disease | 1 | 2000 | 2036 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 10 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 28 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 104 | 0.020 |
Why?
|
| Fatigue | 1 | 2008 | 49 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1989 | 236 | 0.020 |
Why?
|
| Carboplatin | 1 | 2006 | 25 | 0.020 |
Why?
|
| Thiadiazoles | 1 | 1986 | 1 | 0.020 |
Why?
|
| Poverty | 1 | 2007 | 92 | 0.020 |
Why?
|
| Illinois | 1 | 2007 | 235 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 87 | 0.020 |
Why?
|
| Women's Health | 1 | 2007 | 173 | 0.010 |
Why?
|
| Remission Induction | 1 | 2005 | 90 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 126 | 0.010 |
Why?
|
| Oncology Nursing | 1 | 2004 | 2 | 0.010 |
Why?
|
| Patient Selection | 1 | 2005 | 190 | 0.010 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1983 | 6 | 0.010 |
Why?
|
| Imidazoles | 1 | 2004 | 62 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 2 | 0.010 |
Why?
|
| Organizational Policy | 1 | 2003 | 13 | 0.010 |
Why?
|
| Axilla | 1 | 2002 | 14 | 0.010 |
Why?
|
| Mesonephroma | 1 | 1982 | 1 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2002 | 14 | 0.010 |
Why?
|
| Expert Testimony | 1 | 2002 | 12 | 0.010 |
Why?
|
| Mediastinal Neoplasms | 1 | 1982 | 10 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 49 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2002 | 86 | 0.010 |
Why?
|
| Vindesine | 1 | 1981 | 1 | 0.010 |
Why?
|
| Leukopenia | 1 | 1981 | 7 | 0.010 |
Why?
|
| Neuromuscular Diseases | 1 | 1981 | 5 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2002 | 160 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 466 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2001 | 40 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2001 | 33 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 55 | 0.010 |
Why?
|
| Fever | 1 | 2001 | 34 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 757 | 0.010 |
Why?
|
| Palliative Care | 1 | 2001 | 109 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2002 | 851 | 0.010 |
Why?
|
| Pain | 1 | 2001 | 395 | 0.010 |
Why?
|
| Translations | 1 | 1997 | 6 | 0.010 |
Why?
|
| Self Concept | 1 | 1997 | 39 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2002 | 1107 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 473 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1997 | 649 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1994 | 91 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 1994 | 12 | 0.010 |
Why?
|
| Cell Separation | 1 | 1994 | 23 | 0.010 |
Why?
|
| Cisplatin | 1 | 1994 | 60 | 0.010 |
Why?
|
| Anthracenes | 1 | 1983 | 4 | 0.000 |
Why?
|
| Tomography | 1 | 1982 | 13 | 0.000 |
Why?
|
| Radiography, Thoracic | 1 | 1982 | 27 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1982 | 165 | 0.000 |
Why?
|
| Mortality | 1 | 1982 | 87 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1982 | 207 | 0.000 |
Why?
|